| ACP | acyl carrier protein |
| AMP | antimicrobial peptide |
| BCS | Biopharmaceutical Classification System |
| CC | combinatorial chemistry |
| CDC | Centers for Disease Control and Prevention |
| CNS | central nervous system |
| ECDC | European Center for Disease Prevention and Control |
| EMA | European Medicines Agency |
| EPI: | efflux pump inhibitor |
| ETH | ethionamide |
| FDA | Food and Drug Administration |
| HTS | high-throughput screening |
| IDSA | Infectious Diseases Society of America |
| IM | inner membrane |
| IMI | Innovative Medicines Initiative |
| INH | isoniazid |
| IV | intravenous therapy |
| MDR | multidrug resistant |
| MRSA | methicillin-resistant Staphylococcus aureus |
| NAD | nicotinamide adenine dinucleotide |
| ND4BB | New Drugs 4 Bad Bugs |
| OM | outer membrane |
| PO | oral therapy |
| POA | pyrazinoic acid |
| PYR | pyrazinamide |
| PDR | pandrug resistant |
| RDD | rational drug design |
| ROS | reactive oxygen species |
| R&D | research and development |
| RO5 | Lipinsky’s Rule of Five |
| TB | tuberculosis |
| XDR | extensively drug resistant |
| WHO | World Health Organization |